Pathway analysis reveals that AVJ16 treatment leads to a downregulation of the WNT pathway, implicated in lung cancer tumorigenesis, and the genes affected are, in most cases, IGF2BP1-regulated genes, as validated by the shRNA knockdown of IGF2BP1 and confirmed by co-expression analysis. The gene discussed is IGF2BP1; the disease is lung cancer.